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ABSTRACT 
Water solubility and low bioavailability of active pharmaceutical ingredients are some of the main challenges in the process of developing new 
drugs, especially drugs in oral solid dosage forms. One way to improve drug solubility is the principle of cocrystallization. Cocristallyzation itself is 
the process of combining the active ingredients of a less water-soluble drug with a coformer so that it becomes more soluble. Pharmaceutical 
cocrystal provides benefits to improve physicochemical properties without affecting its pharmacological properties. In this review, we have 
reviewed literature discussions and research that discuss co-crystallization as an aid to improve the physicochemical and bioavailability of drugs 
and also discuss some drugs in the form of cocrystal and their improvement in physicochemical-biopharmaceutical properties. The main references 
data used in this review are research journals published in the past 10 y (2010-2020) using keywords: cocrystal, physicochemistry, bioavailability, 
and solid dosage form, and using google scholar as a database. Discussion on the effect of cocrystal on physicochemical properties and 
bioavailability of drugs was produced. The method of producing cocrystal and its characterization was also discussed. Cocrystal offers a promising 
approach to improve the physicochemical properties of API. The benefits of cocrystal can be observed through increased solubility, dissolution rate, 
permeability, bioavailability, drug stability, and tabletability. 
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INTRODUCTION 
The quality of a drug is influenced by various factors. One of them is 
the physicochemical properties of the active pharmaceutical 
ingredient (BAF) or the active pharmaceutical ingredient (API) used. 
The solubility and permeability of drugs are classified in a system 
called the Biopharmaceutical Classification System (BCS). BCS is a 
system used to classify drugs based on their solubility and 
permeability. These factors are very important because most of the 
drugs sold in the world are administered orally [1]. About 60-70% of 
the compounds of new drug drugs discovered in recent years belong 
to the BCS Class II (low solubility-high permeability) and Class IV 
(low solubility-low permeability) [2]. 
The effect of a drug is directly influenced by the solubility of the 
drug, because its therapeutic effectiveness is highly dependent on 
the solubility of the drug in the blood. Drugs that have good 
solubility properties will also have a good absorption profile in the 
intestine, resulting in good bioavailability or bioavailability [3]. The 
absorption of the drug is slower when the solubility is low, resulting 
in lower blood levels of the drug than the therapeutic levels [4]. 
Pharmaceutical researchers have developed a wide variety of 
approaches to increase the solubility of drugs, which in turn leads to 
increased bioavailability. Particle size reduction, solid dispersion, 
complexation, salt formation, nanoparticles, co-solvent addition, 
nanoemulsion suspension, and cocrystal formation are some of the 
approaches used in increasing the solubility of drugs with poor 
water solubility. Among all these methods, the cocrystal approach is 
unique, because it does not affect the pharmacological properties of 
the drug but can improve the bioavailability of the drug as well as 
some of its physicochemical characteristics such as melting point, 
tabletability, stability and permeability [5]. 
In this article, a systematic review or overview is presented of 
pharmaceutical cocrystal, the methods that have been used in their 
production, and also their applications in the pharmaceutical field. 
Apart from that, it also discusses the physicochemical properties, 
characterizations commonly used in drug delivery and laboratory 
development, as well as available literature data on the performance 
of cocrystal in improving physicochemical properties and 
bioavailability. The final part of this review will briefly discuss 
patent property rights as well as regulations related to cocrystal that 
currently exist. 
Cocrystal definition 
Cocrystal is a method that can be used to increase the solubility and 
chemical stability of drugs. A cocrystal is a solid material consisting 
of two or more solid materials that form a new, distinct crystal 
lattice, connected by hydrogen bonds such as the Van der Waals 
bond [6]. The FDA in its Guidance in 2018 explained that cocrystals 
are “crystalline materials or materials composed of two or more 
different molecules, one of which is API, in a predetermined 
stoichiometric ratio in the same crystal lattice, which is bound to 
each other by non-ionic bonds. and noncovalen [7]. A cocrystal is a 
combination of a pharmaceutical active ingredient (API) and its 
cocrystal former (coformer). 
The main advantage of this method is that it can improve physical 
properties such as solubility, dissolution, and compressibility, 
without affecting the pharmacological activity of the API [8]. This is 
due to the presence of coformers in the crystal structure which is a 
component of modifying physical properties. The effect on the 
physicochemical properties of the API depends on the available 
coformers [9]. Also, cocrystallization can be used for all active 
pharmaceutical ingredients including acids, bases, and non-ionizable 
molecules [10]. Another unique advantage of cocrystals over more 
common salt forms is that they can be made for non-ionizable APIs 
[10]. As well as drugs in complex forms with sensitive functional 
groups that may not survive exposure to strong acid or alkaline 
reaction conditions [9]. Cocrystal also exists in a stable crystalline 
form and does not require other excipients or additives in the 
formulation [11].  
Cocrystal former (coformer) 
A cocrystal is composed of two components. The first component is 
the API, and the second component is called a coformer. Most of the 
coformers are medicinal excipients, but coformers can also be fellow 
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active pharmaceutical ingredients that have efficacy. Beside, coformers 
can also be in the form of food additives and preservatives. In general, 
the ratio between API and coformer is 1: 1, 1: 2, or vice versa. 
Cocrystal with API that acts as a coformer are called Cocrystal drugs. 
APIs and coformers can be acidic, alkaline or neutral [12].  
In general, the coformer is a small organic acid compound, and a 
coformer capable of interacting with the target API via hydrogen 
bonding is usually preferred. Some of the coformer groups that are 
often used are carboxylic acid, amide, and alcohol groups. These 
functional groups often interact with each other in a cocrystal 
system [13]. The coformer selected must be non-toxic, and 
pharmaceutically acceptable. Currently, there are around 3000 
compounds included in the Everything Added to Food in the United 
States (EAFUS) list formulated by the USFDA. This amount is also 
included in the Generally Recognized as Safe (GRAS) category. These 
compounds are considered safe enough for use in drug production, 
so that they can be used as coformers in the cocrystallization 
process [14]. Some examples of active substance cocrystals and 
coformers discussed in this review are presented in table 1. 
 
Table 1: Pharmaceutical cocrystal and coformers 
Active compund Coformer Methods References 
Curcumin (Secondary Metabolite) Dextrose Solvent Evaporation Kho et al., 2018. [15] 
Quercetin (Secondary Metabolite) Malonic Acid Solvent Evaporation Setyawan et al., 2018[16]  
Ibuprofen (Antiinflamasi, Analgetik) Nicotinamide Solvent Evaporation Yuliandra et al., 2018 [17] 
Atorvastatin (Antikolesterol) Succinic Acid Solvent Evaporation Wicaksono et al., 2019 [18] 
Famotidin (Antiulcer) Malonic Acid Solvent Evaporation Zhang et al., 2019 [19]. 
5-Fluorouracil (Antineoplastic) Hydroxybenzoic Acid 
Aminobenzoic Acid, Sinamic Acid 
Slurry 
Solvent Drop Grinding 
Dai et al., 2016 [20]. 
Hydrochlorothiazide (Diuretic) Nicotinic Acid, Nicotinamide 
Aminobenzoic Acid 
Solvent Drop Grinding Sanphui et al., 2015 [21]. 
Acyclovir (Antivirus) Maleic Acid, Fumaric Acid 
Glutaric Acid 
 Reaction Cocrystallization Yan et al., 2013 [22]. 
Dihidromiricetin (Secondary Metabolite) Urea caffeine Solvent Evaporation Wang et a. l, 2016 [23]. 
Danazol (Endometriosis Treatment) Vanillin Solvent Evaporation Childs et al., 2013 [24]. 
Indometasin (Anti-Inflammation) Saccharin Solvent Evaporation Ferreti et al., 2015 [25]. 
Carbamazepine (Antikonvulsan) Vanillic Acid, Succinic Acid Solvent Evaporation Dalpiaz et al., 2018 [26]. 
Baicalein (Metabolit Sekunder) Caffeine Reaction Crystallization Zhu et al., 2017 [27]. 
Meloxicam (Anti-Inflammation) Carboxylic Acid Slurry Weyna et a. l, 2012 [28]. 
Oxiracetam (Stimulan) Gallic Acid Solvent Evaporation Wang et al., 2012 [29]. 
Simvastatin (Anticholesterol) Nicotinamide, Aspartame 
Tartric Acid, Saccharin 
Solvent Evaporation 
Slurry 
Solvent Drop Grinding 
Solvent Evaporation 
Sopyan et al., 2017 [30] 
Sopyan., 2017 [32]. Sopyan et al., 
2016[31]. 
Sopyan et al., 2017 [32]. 
Paracetamol (Antipyretic) 5-nitroisophtahlic acid Solvent Evaporation Hiendrawan et al., 2016[33]. 
 
Pharmaceutical cocrystals are composed of two molecules namely 
API molecules and coformer molecules which can be other drugs or 
excipients. Usually, the two components are in a neutral state and 
interact with each other through chemical bonds [15]. The main 
basic principle in cocrystal design is the supramolecular synton 
principle, in which the cocrystal coformers are selected based on 
their interaction at the molecular level. The interactions between 
molecules that have the potential to form cocrystal are non-covalent 
interactions, such as hydrogen bonds, π-π, and van der Waals 
interactions. These interactions will produce patterns that can 
collect molecules to form one, two-or three-dimensional 
arrangement of molecules in the crystal. This pattern is called the 
supramolecular sinton [14]. This theory concludes that the 
functional groups contained in the API and their coformers have an 
influence in the formation of the cocrystal, and the coformers with 
the appropriate functional groups can be paired with certain APIs 
that can interact with the functional groups [5].  
Supramolecular sinton can be categorized into two types, namely 
homosinton and heterosinton. Homosinton is a molecular interaction 
that occurs between two of the same functional groups contained in 
the API and its coformers, whereas heterosinton is the interaction 
between two different functional groups [10]. Based on the analysis of 
the structure of cocrystal summarized in the Cambridge Structural 
Database (CSD), it is concluded that hydrogen bonding is the most 
common interaction between molecules found in cocrystal which has 
been reported in various literature and studies. 
A hydrogen bond can be formed because of the non-covalent 
interaction between the donor group and the hydrogen bond acceptor. 
The first example can be seen from fig. 1. In fig. 1 where the hydrogen 
bond homosinton formation of carboxylic acids between C = O and H-O 
is formed. The homosynthon formation can also be found in fig. 3, 
where a homosynthon formation is formed on the amide group 
between C = O and H-N in the form of a hydrogen bond. Besides 
homosinton, the form of heterosinton interaction can also be observed 
in fig. 2 which occurs between carboxylic acids, and pyridines, 
carboxylic and amides in fig. 4 and alcohol-ether in fig. 5 [10]. 
 
 
Fig. 1: Hydrogen bonds in cocrystallization [10] 
 
The cocrystallization stage begins with the study of the structure of 
the API molecule to be used and identifying the location of the 
hydrogen bond that can occur. Next is the stage of selecting a 
suitable coformer with the API molecule that is being targeted. 
Coformer selection is the most important stage in the design and 
screening process for cocrystal. This process can be done through an 
experimental method on trial and error against all available 
coformers, then characterized to confirm the formation of a 
cocrystal. Currently, many new coformer selections methods have 
been developed, one of which is virtual in silico screening method. 
After the coformer was determined, a screening process was carried 
out with a small-scale cocrystallization experiment. Each 
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cocrystallization method has the possibility of producing cocrystals 
in a new form which cannot be obtained by other methods. So that if 
successful, this process can be continued by increasing the scale of 
production (scale-up) and using different techniques to provide 
more complete results [14].  
In silico screening 
The in silico method aims to predict the possible molecular 
interactions between coformers and active ingredients. The 
coformer selected for in silico screening has several criteria, namely: 
it has no pharmacological activity and has a hydrogen donor or 
acceptor group that has the potential to form hydrogen bonds 
between the API and the coformer [16]. This method is applied by 
performing a molecular docking simulation between the API and the 
coformer computationally using software (for example: Autodock4, 
Dock, EUDOC, Glide, GOLD) to predict the conformation and 
orientation of a small molecule/ligand (coformer) that has lowest 
energy when interacted with the binding site on the target 
macromolecule (API). The accuracy of this method can also be 
improved by calculating the free energy of binding (FEB) between 
the ligand and the target molecule. So that from all the coformers 
tested, it can be determined which coformers have the potential to 
form a cocrystal with the selected API [17]. 
The application of the insilico screening method can be studied from a 
study conducted by Siswandi and friends in 2015. Ketoprofen is a non-
steroidal anti-inflammatory and analgesic drug that is practically 
insoluble in water, but has good permeability so that it is categorized 
in BSC Class II. Thus, a virtual coformer screening technique in silico 
was developed for the co-crystallization of ketoprofen using the 
molecular docking method. The software used is ChemOffice, 
Portable_Hyperchem_8.0, Autodock 4.2.3 and OpenBabelGUI 2.2.3. The 
2D structure of ketoprofen and its coformer were geometrically 
optimized using Portable_Hyperchem and then calculated the QSAR 
characters. Then the entire molecule file is converted into. pdb format 
using OpenBabelGUI 2.2.3 software, then converted back to pdbq and 
pdbqt formats by adding polar hydrogen, Kollman charges and 
calculating the torque angle. The docking process was repeated at 
least 10 times for each coformer and observed the type parameters 
and interaction energy values (Ei). In general, the parameters that can 
assist in the prediction of cocrystal are the type of interaction, bond 
energy, bond distance and molecular conformation [16]. 
Effect of cocrystal on active pharmaceutical properties 
The main objective of the application of pharmaceutical 
cocrystallization is to improve problematic properties such as 
solubility, dissolution rate, bioavailability and stability [18].  
Solubility and dissolution 
Cocrystal will have different solubility with each constituent 
component due to changes in crystal structure [19]. Currently, about 
60-70% of the existing drugs are classified as Class II and IV [2], so 
that efforts to increase the solubility of the drug are needed to 
develop the dosage formulation. In 2018, Katherine and her friends 
did the preparation and characterization of curcumin and dextrose 
cocrystal. Curcumin is a secondary metabolite compound in the 
yellow polyphenol group that comes from the extraction of turmeric 
(Curcuma longa) and is believed to have antioxidant, anti-
inflammatory and anticancer activities. 
The water solubility of curcumin was 0.6 μg/ml. As a coformer, 
dextrose is used because it is widely available and is also a safe 
compound or generally regarded as safe (GRAS). Cocrystal synthesis 
was carried out using the solvent evaporation method. The result is 
curcumin-dextrose cocrystal with high solubility and stability at 
acidic pH. The low initial concentration of curcumin in co-
crystallization (0.2% curcumin) results in higher yield (over 90%) 
and also higher solubility. This indicates that the cocrystallization 
process runs more efficiently at low concentrations. The solubility of 
curcumin-dextrose cocrystal was also higher than that of pure 
curcumin, where the solubility increased to 23 mg/ml at the initial 
curcumin concentration of 0.2%. This increase is thought to be due 
to the formation of hydrogen bonds from the hydroxyl dextrose 
group with the carbonyl or phenolic groups of curcumin. However, 
these studies have not provided results related to in vitro 
dissolution, so further research is needed [15].  
Setyawan and friends also conducted research on the dissolution rate 
of quercetin cocrystal which is a secondary metabolite of the flavonoid 
class. Quercetin has a solubility of 0.3 μg/ml in water and has anti-
cancer, antibacterial and antiviral effects. Quercetin cocrystal is 
prepared by the solvent evaporation method with the malonic acid 
coformer. The results showed that the dissolution rate of quercetin-
malonic acid cocrystal was 95.30% at the 60th minute, higher than the 
dissolution of pure quercetin and also the physical mixture of 
quercetin-malonic acid which had a value of <60% at the 60th minute. 
The test results are also expressed as the percentage dissolution 
efficiency (% DE) of the total drug dissolved in the dissolution medium 
during the test. This percentage can be determined by measuring the 
area under the curve or the area under curve (AUC) obtained from the 
dissolution curve. Quercetin cocrystal gives% DE of 82.57±2.81%, 
higher than pure quercetin (64.46±0.93%) and its physical mixture 
(64.56±0.26%). Several mechanisms are thought to be involved in 
increasing the dissolution rate of quercetin in the cocrystal, such as the 
solubilization of the malonic acid coformer which is a water-soluble 
compound, as well as a decrease in crystal lattice energy and an 
increase in solvent affinity for the cocrystal [19]. 
Cocrystallization is also applied to drugs that have become drug of 
choice in their use. One of them is a research conducted by Yuliandra 
and friends about the synthesis of ibuprofen cocrystal and its 
characterization and evaluation of its analgesic activity in vivo. 
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that is 
included in Class II. As a coformer, nicotinamide is used to increase 
its solubility. The cocrystal was prepared using the slow evaporation 
method and then characterized. In addition, analgesic activity testing 
was also carried out using male mice. The solubility test results 
showed that cocrystal formation could significantly increase the 
solubility of ibuprofen compared to the physical mixture and pure 
ibuprofen. This increase in solubility in the cocrystal phase is 
thought to occur due to the hydrotropic effect of the nicotinamide 
coformer and the increase in affinity in water due to changes in the 
crystal lattice molecules. This increase in solubility also affects the 
analgesic effect of ibuprofen in vivo. The test results showed that the 
cocrystal provides the highest degree of pain inhibition compared to 
pure ibuprofen and its physical mixture [20]. 
Cocrystal can also be applied to anti-cholesterol drugs such as 
Atorvastatin. Wicaksono and his friends succeeded in the preparation 
and characterization of atorvastatin calcium cocrystal in 2019. 
Cocrystal was prepared using the solvent evaporation method with 
methanol and succinic acid coformer. The cocrystal obtained was 
successful in providing a significant increase in solubility compared to 
pure calcium atorvastatin. The increased solubility is also 
accompanied by an increase in the rate of dissolution. Atorvastatin-
succinic acid cocrystal gave a dissolution test result of 47.1±1.9% in 30 
min, much higher than pure calcium atorvastatin which had a 
dissolution rate of 33.6±2.3% at the same time. At the end of testing, 
the percentage of drug release during the dissolution process of 
cocrystal has increased by 1.5 times compared to the pure drug [21]. 
Zhang and colleagues performed synthesis and dissolution analysis 
of Famotidine cocrystal, a drug with an H2 receptor antagonist 
mechanism commonly used to treat gastrointestinal reflux disease 
and is also insoluble in cold water. The preparation was carried out 
using the solvent evaporation method with methanol solvent for 2 d 
and malonic acid coformer. The test performed gave the result of a 
dissolution rate with a maximum concentration of 4.06 mg ml-1 
after 30 min, compared to the maximum concentration of pure 
famotidine, namely 0.96 mg ml-1 after 8 h. So that the famotidine-
malonic acid cocrystal showed an increase of 4.2 times compared to 
the pure drug [22]. 
In the past ten years, research on cocrystal has grown rapidly, but 
little research has been done on the preparation and evaluation of 
cocrystal in tablet dosage forms. One of them is a study in 2019 by 
Budiman and friends on the development of a tablet formulation of 
glibenclamide-saccharin cocrystal to increase the dissolution rate of 
the drug. Glibenclamide is a type 2 antidiabetic drug included in BCS 
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Class II with a solubility of about 4 mg/liter and a bioavailability of 
40-45%. This study is a continuation of previous studies which 
concluded that glibenclamide-saccharin cocrystal can increase the 
solubility of glibenclamide compared to its pure form. Glibenclamide 
cocrystal was prepared using the solvent drop grinding method and 
the saccharin coformer. The resulting cocrystal is then formulated 
into direct compressed tablets. The formula used consists of 
glibenclamide-saccharin cocrystal, magnesium stearate and 
ludipress, with 3 variations of the formula. Then the tablet was 
evaluated and also the in vitro dissolution test. As a result, all 
cocrystalline tablet formulas gave total drug release values of>80% 
within 60 min. Cocrystal tablets with a molar ratio of glibenclamide: 
saccharin of 1: 2 gave the highest percentage of drug release 
compared to the other two formulas, namely as much as 97.68% in 
45 min. So that the dissolution rate of the tablets was 32.36% 
greater than pure glibenclamide after 45 min [23]. 
Permeability 
Another key parameter in the process of oral drug absorption is the 
permeability of the drug as it passes through the biological 
membrane [24]. Compared to research on the effect of cocrystal on 
solubility and dissolution rate, the effect of cocrystal on drug 
permeability has not been widely carried out. 5-fluorouracil (5-FU) 
is a drug in BCS class III whose permeability was successfully 
increased in a study conducted by Dai and friends in 2016 using a 
coformer of 3-hydroxybenzoic acid, 4-aminobenzoic acid and 
cinnamic acid. 5-fluorouracil is an antineoplastic drug used to treat 
skin cancer and other skin diseases via the transdermal route. As a 
result, there was no increase in cocrystal solubility, but an increase 
in permeability. The increase in permeability that occurs is not 
uniform, where the 5-FU-cinnamic acid cocrystal gave the largest 
increase. Supramolecular sinton formation, drug-coformer 
interactions and molecular arrangement in crystals are thought to 
be the cause of the increase in permeability of 5-FU cocrystal. In 
addition, this study also confirms that cocrystals can be used to 
increase drug permeability without affecting their solubility [25].  
Sanphui and colleagues conducted a permeability study of 
hydrochlorothiazide cocrystal (HCT) with coformer nicotinic acid, 
nicotinamide, 4-aminobenzoic acid, succinamide and resorcinol 
using the Franz cell diffusion method. Hydrochlorothiazide is a 
diuretic drug with class IV BCS. The results showed that the amount 
of drug flux present in almost all cocrystal is higher than the pure 
drug except HCT-succinamide. Cocrystals made from the 
succinamide coformer are an exception because they show lower 
amounts than the pure drug. HCT-nicotinic acid cocrystal has 
increased permeability along with decreased solubility. This 
suggests a potential trade-off between solubility and permeability. 
From recent study, it was concluded that the permeability of 
cocrystal can be increased because there is the formation of 
heterosinton interactions between drugs and coformers on the 
crystal lattice which causes changes in polarity [26].  
Permeability studies were also carried out on acyclovir cocrystal 
which is an antiviral drug and is included in BCS class IV. The 
coformers used are carboxylic acid groups such as maleic acid, 
fumaric acid and glutaric acid. All three provide an increase in 
solubility and dissolution rate. The research was continued by 
conducting in vitro experiments using the Franz cell diffusion 
method. The result is the acyclovir-fumaric acid and glutaric acid 
cocrystal provide higher permeability when compared to the maleic 
salt form. This increase is thought to be due to the good lipophilic 
properties of the coformer selected, and the decrease in crystal 
lattice energy which can be predicted from the decrease in the 
melting point of the cocrystal [27]. 
Bioavailability 
Cocrystals have the potential to improve drug delivery and clinical 
performance by modifying drug solubility and dissolution, which in 
turn have an impact on pharmacokinetics and bioavailability in the 
body [19]. Oral drug absorption is generally composed of two stages. 
First, the drug dissolves in the digestive juices that are secreted in 
the digestive tract. Then the drug molecules will permeate the 
digestive membrane by means of passive diffusion or active 
transport [42]. Therefore, it can be concluded that solubility and 
permeability are two key factors that have an impact on the 
effectiveness of the oral absorption of a drug [14].  
Research conducted by Wang and colleagues in 2016 reported that 
there was an increase in the AUC of rat absorption in 
dihydromyricetin-urea cocrystal and caffeine suspended in a 2% 
solution of polyvinyl pyrrolidone K30 (PVP K30), compared to 
dihydromyricetin dihydrate. This increase in bioavailability is 
thought to be due to the effect of a lower rate of precipitation on the 
cocrystal as well as its ability to maintain supersaturation over a 
longer time [28]. Supersaturation occurs when the drug molecules 
contained in a solution have a concentration higher than the 
equilibrium solubility of the stable form of the drug. To extend the 
supersaturation, it is possible to add materials that act as 
crystallization inhibitors and solubilizers [30]. 
Childs and colleagues have also investigated the effect of 
crystallization inhibitor and solubilizer excipients on the in vitro 
dissolution profile and oral absorption of danazol-vanillin cocrystal. 
The cocrystal was previously suspended in 1% tocopheryl 
polyethylene glycol-1000 succinate as a solubilizer and 2% 
hydroxypropyl cellulose as a crystallization inhibitor. This formula 
was successful in obtaining higher degrees of supersaturation and 
also extending the supersaturation level for a longer period in vitro 
dissolution studies in mice, where there was a 10-fold increase in 
AUC compared to the regular solid form of danazol [31].  
Ferreti and colleagues conducted in vitro cellular permeability 
experiments on indomethacin, indomethacin cocrystal, and also 
their physical mixtures. The coformers used were hydroxy-4-
methyl-pyridine, 2-methoxy-5-nitroaniline, and saccharin. 
Meanwhile, the cells used were epithelial colonic cells NCM460. The 
result is indomethaccharin-saccharin cocrystal provides increased 
apparent permeability without causing damage to cells. However, 
there is a difference when compared to the physical mixture of 
indomethacin-saccharin, where the NCM460 cells are damaged [32]. 
This study shows that cocrystals and their physical mixtures can 
react differently to biological membranes. In a later study, Dalpiaz 
and colleagues found that the carbamazepine cocrystal and its 
physical mixture also showed different effects on the cell monolayer 
of NCM460. This difference is thought to be influenced by the 
formation of molecular aggregates in solution [33]. 
Zhu and colleagues synthesized cocrystal baicalein-caffeine which 
was tested for its pharmacokinetic effect in mice. The AUC shown by 
the cocrystal has a difference of 4.1 times greater than that of pure 
baicalein due to the higher dissolution rate of the cocrystal. The 
baicalein-caffeine physical mixture also showed a 2-fold increase in 
AUC compared to pure baicalein. This increase is thought to occur 
due to the synergistic effect of caffeine on the absorption of baicalein 
[34]. This study as well as several other experiments indicates that 
special attention is needed in designing cocrystals composed of 
drugs (cocrystal drugs), because there can be drug-drug 
pharmacokinetic interactions between the constituent components 
of cocrystal. 
Stability 
Drug stability can affect the efficacy and safety of drugs during the 
manufacturing, transportation, distribution and storage processes. 
Pharmaceutical cocrystallization is one way to deal with problems 
related to stability [14]. Some of the stability tests that are 
commonly performed include chemical stability, thermal stability, 
solution stability and relative humidity (RH) stress [5]. Changes in 
relative humidity should be taken into account in the development 
of cocrystal, and other solid dosage forms. To determine this 
parameter, it is generally carried out to test the effect of water 
absorption on the cocrystal. The absorption of water content can be 
controlled by exposing the cocrystal sample to a certain RH value 
using a humidity chamber then analyzing the changes that occur in the 
sample after reaching equilibrium [35]. Research conducted on 
cocrystal 2-[4-(4-chloro-2-fluorphenoxy) phenyl] pyrimidine-4-
carboxamide and glutaric acid coformer gave results in the form of a 
water content value of <0.08% at 95% relative humidity. This 
indicates that the cocrystal is stable in terms of relative humidity [36].  
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Other studies were carried out on caffeine which was crystallized 
with several coformers of the carboxylic acid groups such as oxalic 
acid, malonic acid, maleic acid, and glutaric acid. The cocrystal 
samples were exposed to four different RH conditions, and analyzed 
for a period of 1, 3 and 7 w. As a result, caffeine-oxalic acid cocrystal 
showed stability to humidity (moisture) at all RH conditions. So, it 
can be concluded that the cocrystal has less hygroscopicity than the 
pure active ingredient [6]. Oxiracetam (OX) cocrystal (in the form of 
racemic S-OX and R-OX) and gallic acid coformer tested at RH 
conditions of 43, 75, 87, and 98% for 8 w showed improved 
hygroscopic stability compared to their initial form. S-OX cocrystal 
and gallic acid were stable in all RH conditions for 8 w [37]. Apart 
from relative humidity, high temperatures can also be used to 
predict the physical and chemical stability of cocrystal [38]. 
Paracetamol cocrystal with a 4,4-bipyridine coformer showed 
increased stability compared to the 1,4-dioxane, N-methyl 
morpholine, morpholine, N, N-dimethyl piperazine, and piperazine 
coformers when heated with a differential scanning calorimetry 
(DSC) instrument [39].  
Other studies have shown that there is no degradation or 
polymorphic transition on the stability test of monophosphate salt 
cocrystal and phosphoric acid coformer at 60 °C [40]. RH and high 
temperatures can also be used together in stability tests. Research 
on the stability of simvastatin-nicotinamide (1: 1) cocrystal stored in 
storage conditions at 40oC and 75% RH for one month, did not show 
any changes in the melting point on days 10, 20 and 30 these 
conditions [8]. 
Tabletability 
Changes in the crystal structure due to cocrystallization can trigger 
changes in the mechanical properties of the cocrystal, one of which 
is tabletability [35]. Previous studies have concluded that the results 
of the co-crystallization experiment can produce cocrystal with 
increased or decreased mechanical properties [41]. Tabletability is 
defined as the ability of a material to be formed into tablets that 
have a specific strength or power under the influence of a printing 
pressure force [42]. 
Paracetamol (PCA) was crystallized with the 5-nitro isophtahlic acid 
(5NIP) coformer to improve its tabletability. Cocrystal synthesis was 
carried out by the solvent evaporation method using methanol as a 
solvent. The resulting cocrystal was then characterized and 
evaluated, including an analysis of powder compaction. Cocrystal 
samples of PCA-5NIP and pure PCA were sieved with a sieve no. 60 
(mesh size 250 μm). Then as much as 500 mg of sample powder was 
put into a tablet mold and printed at a pressure of 4.9-29.4 kN using 
a hydraulic press, with a tablet diameter of 13 mm. Then the tablets 
were left to stand for one night, and their diameter, thickness, and 
hardness were measured. The tabletability profile is obtained by 
calculating the tensile strength of the tablets and plotting it as a 
function of compaction pressure. Compared to pure PCA, PCA-5NIP 
cocrystal showed a better tabletability profile. The tensile strength 
of the PCA-5NIP cocrystalline tablet al. so increased with increasing 
printing pressure [33]. This difference is thought to occur due to the 
formation of hydrogen bonding layers in the crystal structure [43]. 
There is also a theory that the crystal lattice has higher plasticity and 
thus results in stronger tablets [44]. 
Preparation of cocrystal 
Cocrystal synthesis can be carried out by several methods which are 
generally categorized into solid-based and solvent-based methods. 
Solid-state or solvent-free methods use little or no solvent and are 
usually aided by the application of mechanical energy to the 
cocrystallization process. Neat grinding, liquid assisted grinding, 
polymer assisted grinding and hot melt extrusion are methods that 
fall into this category. The solvent-based method is a technique 
commonly used for cocrystallization and uses a solvent or solvent 
mixture in the process. The solvent method consists of solvent 
evaporation, cooling cocrystallization, the addition of anti-solvent, 
and slurrying. Various new methods of cocrystal synthesis have also 
been developed, including the use of supercritical fluid, spray drying, 
freeze-drying, and high-pressure homogenization. A summary of the 
methods for making cocrystal is presented in table 2. 
 
Table 2: Method of cocrystal preparation 
Method 
category 




Neat grinding (dry 
grinding, solid state 
grinding) 
Mixing and grinding of active substances and coformers 
in stoichiometric ratios over a period of time, manually 




al., 2011 [45]. 
 
Liquid assisted 
grinding (solvent drop 
grinding) 
Mixing and grinding of cocrystal components with the 
addition of a small amount of solvent, manually or 
mechanically over a while [12, 46]. 
Didanosine-benzoic acid 
and salicylic acid [54]. 




The use of polymers in solid/liquid form as a 
cocrystallization catalyst [12]. 
Caffeine-glutaric acid 
[46]. 
Hasa et al., 
2016 [46]. 
Hot melt extrusion Cocrystallization uses high heat and pressure to melt 













Solvent evaporation of a saturated solution of a mixture 
of the active substance and coformer, at room 
temperature [38, 48]. 
Artesunat-nicotinamide 




Cocrystallization in a solution of a mixture of active 
substances and coformers by cooling/reducing 
temperature [19, 50]. 
Theophylic acid 
benzoate [51]. 
Huang et al., 
2019 [51]. 
Antisolvent Cocrystallization in a solution of active substances and 
coformers due to the addition of an antisolvent mixture 
(ethanol/water, ethanol/acetonitrile, ethanol/ethyl 






Slurry (pembuburan) Cocrystallization by adding a solid of the active 
substance/coformer into the solvent/solvent mixture to 
form a slurry [16]. 
Indometasin-
nicotinamide [54]. 





Supercritical Fluid Addition of supercritical solution (CO2) to the solid 





Spray Drying Removes solvent from the mixed active 
substance/coformer solution rapidly by dispersing it in 
a nitrogen hot air stream [19, 57]. 
Itrakonazole-suberic 
acid [58]. 
Weng et al., 
2013 [58]. 
 
Freeze Drying Rapid freezing of the active substance/coformer 
mixture solution which causes sublimation of the 





Eddleston et al., 
2019 [59]. 
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Homogenization of the active substance/coformer 




Fernánde et al., 
2013 [61]. 
 
Evaluation and characterization of cocrystal 
The effect of cocrystallization on the properties of the active substance 
can be determined by evaluating the resulting cocrystal solids. 
Evaluation of cocrystal can be done by solubility test, dissolution test, 
and stability test. The evaluation data can be supported by 
characterization data to ensure that the resulting product is a cocrystal 
and not another solid form. Several methods have been applied for the 
characterization of pharmaceutical cocrystals. Characterization can be 
carried out on the structure and physical properties of the cocrystal. 
The structure of the cocrystal can be analyzed using infrared 
spectroscopy (FTIR) methods and X-ray diffraction or powder x-ray 
diffraction (PXRD), while the physical properties are analyzed using a 
melting point measuring instrument such as differential scanning 
calorimetry. A summary of the evaluation and characterization of 
cocrystal is presented in table 3. 
 
Table 3: Evaluation and characterization of cocrystal 
Evaluation Description Submited cocrystal References 
Solubility test To determine the solubility of cocrystal 
compared to pure drugs or physical mixtures 
thereof. The cocrystal sample and the medium 
are put into an Erlenmeyer flask or other 
containers, then shaken for 24 h at room 
temperature in the tool. rotary flask shaker or 
orbital shaker. After 24 h, the sample is 
filtered, diluted and measured with HPLC or 
UV at the appropriate wave [71]. 
Ibuprofen-nicotinamide by solvent evaporation. The 
test results analyzed by one-way ANOVA indicate a 
significant increase in solubility. The solubility of 
ibuprofen cocrystal is also better compared to the 
physical mix. Obtained p-value<0.05 and p<0.01 
compared to pure ibuprofen. The results of the 
solubility characterization of ibuprofen-nicotinamide 
cocrystal are shown in fig. 2 [62]. 
Yuliendra et al., 
2018 [62]. 
 Dissolution test To know the increase in the dissolution rate of 
cocrystal. Used to confirm drug release over 
time and predict in vivo performance. 
Cocrystal samples were tested using a paddle 
or rotating basket type dissolution tester in a 
suitable dissolution medium. Then the sample 
is taken in an appropriate amount at 
predetermined time intervals and then 
analyzed using HPLC or UV instruments [63]. 
Famotidine-malonic acid with solvent evaporation. 
Fig. 3 shows the increased dissolution of famotidine-
malonic acid cocrystal, seen from the maximum 
famotidine concentration value of 4.06 mg ml-1 after 
30 min. So that the cocrystal showed an increase of 4.2 
times compared to pure famotidine [19].  
Diacarein-urea, tartrate acid. Fig. 4. Shows the percent 
drug release in the diacerein cocrystal dissolution test. 
Diacerein-urea cocrystal showed a higher dissolution 
rate (91.31%) than diacarein-tartaric acid cocrystal 
(83.13%) and commercial diacarein (46.88%) within 
60 min [64]. 




To determine changes in chemical structure 
and molecular interactions that occur in the 
cocrystal lattice. The cocrystal sample was 
formed by KBr crystal pellets and measured 
using an IR spectrophotometer at a 
wavenumber of 4000-400 cm-1,[65]. 
Ketoconazole-ascorbic acid by slurrying. The 
ketoconazole spectrum in fig. 5. shows the presence of 
unique peaks at 1647 cm-1 (C = O), 1582 cm-1 (C = C), 
and 1512 cm-1 (C = C). Whereas in cocrystal, there is a 
change in the infrared band compared to the 
constituent compounds. The main IR spectrum peaks 
of the C=O group on ketoconazole and ascorbic acid 
can be observed at wavenumbers 1647 cm-1 and 1755 
cm-1, but the same groups are detected at 
wavenumbers 1643 cm-1 on ketoconazole-ascorbic 
acid cocrystal [66]. 




To find out the crystalline structure of the 
cocrystal. The patterns obtained from the 
diffractometer are compared with one 
another. The different XRD patterns between 
the cocrystal and its constituent components 
indicate the formation of the cocrystal [5]. 
Glibenclamide-oxalate acid with solvent drop grinding. 
Fig. 6. shows the PXRD spectra of glibenclamide, oxalic 
acid, glibenclamide cocrystal: 1: 1 and 1: 2 oxalic acid 
(fig. 6). The results indicated that there was a 
formation of cocrystal between glibenclamide and 
oxalic acid. On the diffractogram, there is a difference 
in peak intensity (peak) on glibenclamide cocrystal 
with a ratio of 1: 1 from 18472 to 15643. Besides, 
there is the formation of new peaks at 2θ = 30-40 °C 
with a peak intensity of 3306 [67]. 
Budiman A. et 




To detect cocrystal formation, look at the 
appearance of an exothermic peak followed by 
an endothermic peak, or change in the melting 
point of the DSC spectrum. More than 50% of 
cases show that the melting point of the 
cocrystal is lower than the melting point of the 
respective active ingredients and their 
coformers [37]. The pure drug, coformer, 
physical mixture, and cocrystal are placed on 
the aluminum pan and analyzed with a 
predetermined heating rate [5]. 
Piroxicam-sodium acetate neatly grinding. Fig. 7. 
Showing the thermogram of piroxicam, sodium acetate 
and cocrystal. A difference was found where the 
melting point was at 188.16 °C, in the middle of the 
melting point of pure piroxicam (200.39 °C) and 
sodium acetate coformer (323.5 °C). The peak onset of 
piroxicam was detected at 199.60 °C, while for 
cocrystal it was detected at 182.57 °C [68]. 
Indra et al., 
2019 [68]. 
Stability evaluation Comparing the stability and shelf life of 
cocrystal and pure active substances. Typically 
used temperature and humidity are 40 
°C/75% RH [30, 67, 69] and 25 °C/60% for 1, 
3 or 6 mo [67, 70]. 
Simvastatin-nicotinamide with solvent evaporation. 
The result was that there was no change in the melting 
point of the cocrystal (105.5 °C) for 1 mo under 
storage conditions of 40 °C and 75% RH [30]. 
Sopyan et al., 
2017 [30]. 
Sopyan et al. 




Fig. 2: The saturated solubility of ibuprofen, physical mixture and ibuprofen-nicotinamide cocrystals [17] 
 
 
Fig. 4: Diacarein cocrystal dissolution test [64] 
 
 
Fig. 5: FTIR spectrum of a ketoconazole (green), ascorbic acid (red) and, cocrystal (blue) [68] 
 
 
Fig. 6: PXRD spectra of glibenclamide (black), oxalic acid (yellow), glibenclamide cocrystal: 1: 1 oxalic acid (blue) and glibenclamide 
cocrystal: 1: 2 oxalic acid (red) [70] 
Sopyan et al. 




Fig. 7: DSC thermogram of a) piroxicam b) sodium acetate and c) piroxicam-sodium acetate cocrystal [71] 
 
Cocrystal regulation 
In addition to discussing the classification of cocrystal following 
regulations, the 2018 FDA guidance also guides industries that will 
apply for pharmaceutical cocrystal products in the form of new drug 
applications (NDA) and abbreviated new drug applications (ANDA), 
along with supporting data that must be included. If the proposed 
cocrystal meets these requirements, it can be categorized as a 
pharmaceutical cocrystal and has the same regulatory classification 
as the polymorph form of the active pharmaceutical ingredient. The 
FDA believes that cocrystalline products are not considered new 
pharmaceutical active ingredients. Because from a regulatory 
perspective, a medicinal product designed to contain a new cocrystal 
is considered the same as the new polymorph form of API. Cocrystal 
consisting of two or more APIs (with or without the addition of a 
coformer) will be considered as a drug product with a fixed-dose 
combination and not a single new API [7]. 
In 2015, EMA also published a reflection paper on the use of 
cocrystal from active ingredients in health products. The EMA 
definitions of cocrystal are in line with the definitions stated in FDA 
guidance but differ for the classification. The FDA classifies 
cocrystals as a new polymorph form of the active ingredient and so 
is not considered a new API. Meanwhile, according to the EMA, 
cocrystal is in the same category as salt by regulation. Because 
cocrystal and salt are thought to have many conceptual similarities 
to salt. Cocrystal can also be applied and documented as a generic 
drug in the same way as salt. To be submitted as a New Active 
Substance (NAS), the cocrystal must be able to demonstrate 
differences in efficacy and safety concerning the original API [72]. 
This opinion is quite contrary to the FDA classification, where a 
different salt form of an API is considered a different or new API, 
while a different polymorph form of an API (in this case including 
cocrystals) is considered the same API. 
Newest cocrystal marketed 
The following are some examples of new medicinal products in the 
form of cocrystal which are currently patented (table 4). 
 
Table 4: Cocrystal patent in the market 




Tablets with dosage strengths of 5 mg, 10 mg, 15 mg, 20 
mg and 30 mg 
Abilify consists of Aripiprazole compound 
and fumaric acid coformer and is prepared 
using the addition of the anti-solvent Lexapro 
(Escitalopram oxalate) method [73]. 
Devarakonda et al., 
2009 [73]. 
Lexapro Escitalopram oxalate has a dosage strength of 5 mg, 10 
mg and 20 mg [74]. 
The drug consists of the cation escitalopram 
as the main active ingredient, dianone 
oxalate and an oxalic acid coformer [75]. 





Valproate sodium administered orally in tablet form with 
dosage strengths of 125 mg, 250 mg, and 500 mg [76]. 
Valproic acid coformer [35]. Karagianni et al., 
2018[35]. 
Entresto Active ingredients sacubitril and valsartan, available in 
oral tablet form with dosage strengths of 24/26 mg, 
49/51 mg, and 97/103 mg [77]. 
 FDA 2019., [77] 
 
CONCLUSION 
Cocrystal offers a promising approach to improving the 
physicochemical properties of APIs. The benefits of cocrystal can be 
observed through the increase in solubility, dissolution rate, 
permeability, bioavailability, stability, and tabletability of the drug. 
There are quite a several options to choose from in the cocrystal 
manufacturing process, both for small-scale synthesis methods in 
the laboratory and for large-scale sustainable production methods in 
the industry. As the interest and value-added to cocrystal, the 
application of cocrystal in the pharmaceutical field is also growing. 
Cocrystals will certainly be increasingly common in future 
developments in pharmaceuticals. 
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